Market Research Industry Reports

Thromboembolism - Pipeline Review, H2 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Thromboembolism - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism - Pipeline Review, H2 2018, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape.

When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy and surgery.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Thromboembolism - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Thromboembolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thromboembolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 3, 1, 5, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Thromboembolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thromboembolism (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Thromboembolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thromboembolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thromboembolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Thromboembolism (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thromboembolism (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thromboembolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Thromboembolism - Overview
Thromboembolism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Thromboembolism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Thromboembolism - Companies Involved in Therapeutics Development
Bayer AG
China Biologic Products Inc
Daiichi Sankyo Co Ltd
F. Hoffmann-La Roche Ltd
GC Pharma
Ionis Pharmaceuticals Inc
Johnson & Johnson
Portola Pharmaceuticals Inc
Tetherex Pharmaceuticals Corp
Verseon Corp
Thromboembolism - Drug Profiles
antithrombin III (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1213790 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
betrixaban - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
edoxaban tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GCC-2107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-FXIRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-9375 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lysimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Thromboembolism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rivaroxaban - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SelK-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAP-ANV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VE-1902 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VE-2851 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YG-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Thromboembolism - Dormant Projects
Thromboembolism - Discontinued Products
Thromboembolism - Product Development Milestones
Featured News & Press Releases
Jun 14, 2018: Verseon to Initiate Phase I Study to Evaluate a New Precision Oral Anticoagulant with Reduced Bleeding Risk
Jun 07, 2018: Verseon presents new data on its precision oral anticoagulants at BIO International Convention 2018
May 18, 2018: LIXIANA (edoxaban) Shows Reduced Rate of a Variety of Types of Intracranial Haemorrhage Compared to Warfarin in New Sub-analysis Presented at the European Stroke Organisation Conference 2018
Mar 23, 2018: Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union
Feb 20, 2018: Portola Pharmaceuticals Announces Results of CHMP Oral Explanation for Betrixaban
Dec 19, 2017: FDA Approves Prior Approval Supplement for Commercial Launch of Portola Pharmas Novel Oral Anticoagulant Bevyxxa (betrixaban)
Dec 13, 2017: Once-Daily, Oral LIXIANA (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study
Nov 30, 2017: Portola Pharmaceuticals to Present New Data on Betrixaban at the 59th American Society of Hematology (ASH) Annual Meeting
Nov 21, 2017: Portola Pharmaceuticals Provides Update on Bevyxxa (betrixaban) Commercial Launch
Nov 07, 2017: Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on Betrixaban to be Presented at the America Heart Association Scientific Sessions 2017
Nov 01, 2017: Janssen to Present Abstracts on XARELTO at ASH 2017
Oct 30, 2017: Bayer receives FDA approval for Xarelto 10 mg once daily for the extended treatment of venous thromboembolism
Sep 15, 2017: Bayer receives positive CHMP opinion for rivaroxaban 10 mg once daily for the extended prevention of venous thromboembolism
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Thromboembolism, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Thromboembolism - Pipeline by Bayer AG, H2 2018
Thromboembolism - Pipeline by China Biologic Products Inc, H2 2018
Thromboembolism - Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Thromboembolism - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Thromboembolism - Pipeline by GC Pharma, H2 2018
Thromboembolism - Pipeline by Ionis Pharmaceuticals Inc, H2 2018
Thromboembolism - Pipeline by Johnson & Johnson, H2 2018
Thromboembolism - Pipeline by Portola Pharmaceuticals Inc, H2 2018
Thromboembolism - Pipeline by Tetherex Pharmaceuticals Corp, H2 2018
Thromboembolism - Pipeline by Verseon Corp, H2 2018
Thromboembolism - Dormant Projects, H2 2018
Thromboembolism - Discontinued Products, H2 2018

List Of Figures

List of Figures
Number of Products under Development for Thromboembolism, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Thromboembolism - Pipeline Review, H2 2018

Thromboembolism - Pipeline Review, H2 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism - Pipeline Review, H2 2018, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape.When

USD 2000View Report

Venous Thromboembolism - Market Insight, Epidemiology and Market Forecast - 2027

DelveInsights Venous Thromboembolism - Market Insight, Epidemiology and Market Forecast - 2027 report provides a detailed analysis of the Venous Thromboembolism epidemiology and market outlook for the 7MM.Markets

USD 6250View Report

Parkinsons Disease - Pipeline Review, H2 2017

Parkinsons Disease - Pipeline Review, H2 2017Latest Pharmaceutical and Healthcare disease pipeline guide Parkinsons Disease - Pipeline Review, H2 2017, provides an overview of the Parkinsons Disease (Central Nervous System)

USD 2500View Report

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2018

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2018Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen

USD 3500View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Jul 2018
No. of Pages :98
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube